Published May 14, 2021
| Version v1
Journal article
Open
An inverse-breathing encapsulation system for cell delivery
Creators
- 1. Cornell University
- 2. University of Chicago
- 3. O2M Technologies LLC
- 4. University of Arizona
Description
Cell encapsulation represents a promising therapeutic strategy for many hormone-deficient diseases such as type 1 diabetes (T1D). However, adequate oxygenation of the encapsulated cells remains a challenge, especially in the poorly oxygenated subcutaneous site. Here, we present an encapsulation system that generates oxygen (O2) for the cells from their own waste product, carbon dioxide (CO2), in a self-regulated (i.e., "inverse breathing") way. We leveraged a gas-solid (CO2-lithium peroxide) reaction that was completely separated from the aqueous cellular environment by a gas permeable membrane. O2 measurements and imaging validated CO2-responsive O2 release, which improved cell survival in hypoxic conditions. Simulation-guided optimization yielded a device that restored normoglycemia of immunocompetent diabetic mice for over 3 months. Furthermore, functional islets were observed in scaled-up device implants in minipigs retrieved after 2 months. This inverse breathing device provides a potential system to support long-term cell function in the clinically attractive subcutaneous site.
Data availability
All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Additional data related to this paper may be requested from the authors.Files
sciadv.abd5835.pdf
Files
(72.2 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:f23504e8ee6c3a01e6e917b1ca22f04a
|
67.9 MB | Preview Download |
|
Article md5:1792728958d7ef9df488f55df189ea92 |
4.3 MB | Preview Download |
Additional details
Identifiers
- DOI
- 10.1126/sciadv.abd5835
- Other
- oai:uchicago.tind.io:10969
Funding
- National Science Foundation
- DGE-1650441
- National Science Foundation
- 1819583
- National Institutes of Health
- 1R01DK105967-01A1
- National Cancer Institute
- R43CA224840
- Small Business Innovation Research
- Small Business Innovation Research
- Small Business Innovation Research
- 1819583
- Juvenile Diabetes Research Foundation
- 2-SRA-2018-472-S-B
- Juvenile Diabetes Research Foundation
- 3-SRA-2020-883-M-B
- Novo Nordisk Company
- Hartwell Foundation